Abstract: Provided are pharmaceutical compositions in solid form comprising a selective modulator of PPAR-? suitable for oral dosage to treat subjects having PPAR-? mediated conditions. Provided further are methods of manufacturing the compositions, and methods of treating a PPAR-? mediated condition.

Abstract: Provided are pharmaceutical compositions in solid form comprising a selective modulator of PPAR-? suitable for oral dosage to treat subjects having PPAR-? mediated conditions. Provided further are methods of manufacturing the compositions, and methods of treating a PPAR-? mediated condition.

Abstract: The present invention relates to pharmaceutical compositions and methods for the treatment of diabetes, obesity or disorders related to diabetes or obesity. The compositions comprise a combination of a particular PPAR? agonist and a particular dipeptidyl peptidase-IV (DPP-IV) inhibitor. The methods include the administration of the combination of a particular PPAR? agonist and a particular dipeptidyl peptidase-IV (DPP-IV) inhibitor.

Abstract: Provided are pharmaceutical compositions in solid form comprising a selective modulator of PPAR-Y suitable for oral dosage to treat subjects having PPAR-Y mediated conditions. Provided further are methods of manufacturing the compositions, and methods of treating a PPAR-Y mediated condition.

Abstract: The present invention relates to pharmaceutical compositions and methods for the treatment of diabetes, obesity or disorders related to diabetes or obesity. The compositions comprise a combination of a selective PPAR? modulator and an incretin. The methods include the administration of the combination of a selective PPAR? modulator and an incretin.

Abstract: Preferred embodiments of the invention provide systems and methods for facilitating user thinking about an arbitrary problem, as well as providing capabilities to output to and interface with external or additional computer systems, resources, or devices, or any combination thereof. The system includes first logic to facilitate user specification of a problem structure, second logic to facilitate user specification of a conclusion structure, third logic to facilitate specification of a knowledge structure, related to the arbitrary problem. The system further includes output and interface logic to accomplish interfacing with a plurality of external or additional computer systems, information sources, resources, or devices.

Abstract: Preferred embodiments of the invention provide a computer-implemented system and method for facilitating user thinking about an arbitrary problem. The system includes first means to facilitate the user specification of the problem to populate a problem structure. It also includes second means to facilitate the user specification of a conclusion, related to the problem specification, to populate a conclusion structure. It also includes third means to facilitate the user specification of knowledge, related to at least one of the problem specification and the conclusion specification, to populate a knowledge structure. Certain embodiments include controlling means to persuade user interaction with the first, second and third means to a sequence of interactions within a predefined set of interaction sequences, wherein the predefined set of interaction sequences define an archetype process for thinking about the problem.

Abstract: The disclosed invention is directed to methods and compounds useful in treating a myelodysplastic syndrome (MDS) using p38 MAP kinase inhibitors either alone or in combination with other chemotherapeutic compounds. A role for p38 kinase inhibition as a treatment modality for combating MDS is discussed herein. Relating to a preferred embodiment, compounds of the invention have been found to inhibit p38 kinase, the ?-isoform in particular, and are useful in treating MDS.

Abstract: The present invention provides assays to identify compounds that affect microglial cell activation, and specifically assays to identify compounds that affect secretion of cytokines from these microglial cells by modulating PGE2-mediated activity. The assays of the invention include assays for testing microglial cell activation by contacting microglia with compounds that modulate ?-amyloid PGE2-mediated activation, which can be identified by cellular activity such as secretion of cytokines, e.g., TNF-? and IL-1?,. The effect of the candidate compound can be determined by comparing the effect with a control culture which is not contacted with the compound, or by comparing the effect with a standardized profile.

Abstract: The present invention provides a method to treat multiple myeloma by the administration of one or more p38 MAP kinase inhibitor(s).

Abstract: The present invention provides a method to treat osteolytic lesions associated with multiple myeloma by the administration of one or more p38 MAP kinase inhibitors.

Abstract: The present invention provides a method to treat multiple myeloma by the co-administration of one or more p38 MAP kinase inhibitors with one or more proteosome inhibitors.

Abstract: The present invention concerns methods of treatment for acute coronary syndrome using a pharmaceutically effective amount of an inhibitor of p38 MAP kinase. More specifically, the invention concerns the treatment of cardiovascular disorders associated with atherosclerosis.

Abstract: The invention concerns methods of treating malignant gliomas, by administering inhibitors of TGF-? the TGF-? signaling pathway, including molecules preferably binding to the type I TGF-? receptor (TGF?-R1). Preferably, the inhibitors are non-peptide small molecules, including quinazoline derivatives. The invention also concerns methods for reversing the TGF-?-mediated effect on glioma cells to make them less refractile to signaling and other immune cells, comprising contacting a glioma cell or tissue in vivo or in vitro, with an inhibitor of TGF-?.

Abstract: Preferred embodiments of the invention provide systems and methods of facilitating and evaluating user thinking about an arbitrary problem. The system includes first logic to facilitate user specification of the problem to populate a problem statement structure. It also includes second logic to facilitate user specification of a conclusion, related to the problem specification, to populate a conclusion statement structure. It also includes third logic to facilitate user creation and specification of knowledge, related to at least one of the problem specification and the conclusion specification, to populate a knowledge structure. Certain embodiments include control logic to persuade user interaction with the first through third logic to a sequence of interactions within a predefined set of interaction sequences, wherein the predefined set of interactions define an archetype process for user thinking about the problem.

Abstract: The invention is directed to methods and compositions that differentially inhibit the ?-isoform of p38 MAP kinase.